PARP Inhibitors Rising as an Epoch-Making Strategy in First-Line Maintenance Therapy of Ovarian Cancer: A Systematic Review and Meta-Analysis.
- Resource Type
- Article
- Authors
- Ying, Zhang; Qi, Du; Chaoran, Wang; Min, Hu; Miao, Wang; Qin, Li
- Source
- Cancer Investigation. Nov2022, Vol. 40 Issue 10, p889-900. 12p.
- Subject
- *THERAPEUTIC use of antineoplastic agents
*ONLINE information services
*OVARIAN tumors
*META-analysis
*CONFIDENCE intervals
*MEDICAL information storage & retrieval systems
*SYSTEMATIC reviews
*TUMOR classification
*DESCRIPTIVE statistics
*DATA analysis software
*MEDLINE
*ENZYME inhibitors
- Language
- ISSN
- 0735-7907
To illustrate the accurate location of Poly-ADP-ribose polymerase inhibitor (PARPi) as the first-line maintenance therapy in advanced ovarian cancer (AOC). Search for eligible studies and calculate clinical outcomes. PARPi as a first-line maintenance treatment significantly prolonged the BRCAmut population and the homologous recombination deficiency (HRD) positive population. PARPi as first-line maintenance therapy significantly improves the progression-free survival in AOC, especially in the BRCAmut and HRD positive populations. PARPi has been becoming the standard first-line maintenance therapy for AOC. [ABSTRACT FROM AUTHOR]